Class information for:
Level 1: INFLIXIMAB//VEDOLIZUMAB//ADALIMUMAB

Basic class information
ID Publications Average number
of references		 Avg. shr. active
ref. in WoS
1506 2535 42.2 86%


Bar chart of Publication_year

Last years might be incomplete

Classes in level above (level 2)


ID, lev.
above		 Publications Label for level above
88 25697 ULCERATIVE COLITIS//CROHNS DISEASE//INFLAMMATORY BOWEL DISEASE

Terms with highest relevance score


Rank Term Type of term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 INFLIXIMAB Author keyword 108 20% 19% 493
2 VEDOLIZUMAB Author keyword 72 91% 1% 30
3 ADALIMUMAB Author keyword 46 20% 8% 205
4 LOSS OF RESPONSE Author keyword 42 78% 1% 28
5 MUCOSAL HEALING Author keyword 40 40% 3% 78
6 CERTOLIZUMAB PEGOL Author keyword 27 49% 2% 41
7 INFLAMMATORY BOWEL DIS Address 18 14% 5% 116
8 JOURNAL OF CROHNS & COLITIS Journal 18 14% 5% 115
9 ANTI INFLIXIMAB ANTIBODIES Author keyword 15 77% 0% 10
10 TOP DOWN THERAPY Author keyword 11 78% 0% 7

Web of Science journal categories

Author Key Words


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class		 LCSH search Wikipedia search
1 INFLIXIMAB 108 20% 19% 493 Search INFLIXIMAB Search INFLIXIMAB
2 VEDOLIZUMAB 72 91% 1% 30 Search VEDOLIZUMAB Search VEDOLIZUMAB
3 ADALIMUMAB 46 20% 8% 205 Search ADALIMUMAB Search ADALIMUMAB
4 LOSS OF RESPONSE 42 78% 1% 28 Search LOSS+OF+RESPONSE Search LOSS+OF+RESPONSE
5 MUCOSAL HEALING 40 40% 3% 78 Search MUCOSAL+HEALING Search MUCOSAL+HEALING
6 CERTOLIZUMAB PEGOL 27 49% 2% 41 Search CERTOLIZUMAB+PEGOL Search CERTOLIZUMAB+PEGOL
7 ANTI INFLIXIMAB ANTIBODIES 15 77% 0% 10 Search ANTI+INFLIXIMAB+ANTIBODIES Search ANTI+INFLIXIMAB+ANTIBODIES
8 TOP DOWN THERAPY 11 78% 0% 7 Search TOP+DOWN+THERAPY Search TOP+DOWN+THERAPY
9 ANTI TNF ANTIBODIES 9 59% 0% 10 Search ANTI+TNF+ANTIBODIES Search ANTI+TNF+ANTIBODIES
10 ANTIBODIES TO INFLIXIMAB 8 70% 0% 7 Search ANTIBODIES+TO+INFLIXIMAB Search ANTIBODIES+TO+INFLIXIMAB

Key Words Plus


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 CERTOLIZUMAB PEGOL 165 62% 7% 172
2 MAINTENANCE INFLIXIMAB 114 72% 4% 89
3 LOST RESPONSE 94 94% 1% 33
4 MAINTENANCE THERAPY 94 22% 15% 375
5 MONOCLONAL ANTIBODY ADALIMUMAB 77 73% 2% 58
6 SERUM INFLIXIMAB 74 84% 2% 41
7 INFLIXIMAB 69 12% 22% 546
8 SINGLE CENTER COHORT 66 74% 2% 50
9 CHARM TRIAL 57 79% 1% 37
10 SCHEDULED MAINTENANCE TREATMENT 53 79% 1% 34

Journals


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 JOURNAL OF CROHNS & COLITIS 18 14% 5% 115
2 REVIEWS IN GASTROENTEROLOGICAL DISORDERS 2 15% 0% 10

Reviews


Title Publ. year Cit. Active references % act. ref.
to same field
Impact of Antibodies to Infliximab on Clinical Outcomes and Serum Infliximab Levels in Patients With Inflammatory Bowel Disease (IBD): A Meta-Analysis 2013 66 43 84%
Efficacy of Biological Therapies in Inflammatory Bowel Disease: Systematic Review and Meta-Analysis 2011 154 50 78%
Optimizing anti-TNF treatments in inflammatory bowel disease 2014 24 53 81%
Systematic review with meta-analysis: the efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF treatment has failed 2015 3 67 94%
Biological Therapies for Inflammatory Bowel Diseases 2009 183 65 77%
Loss of Response and Requirement of Infliximab Dose Intensification in Crohn's Disease: A Review 2009 142 38 95%
Opportunistic Infections With Anti-Tumor Necrosis Factor-alpha Therapy in Inflammatory Bowel Disease: Meta-Analysis of Randomized Controlled Trials 2013 45 48 83%
Systematic review with meta-analysis: malignancies with anti-tumour necrosis factor-alpha therapy in inflammatory bowel disease 2014 21 53 77%
The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD With the European Crohn's and Colitis Organization: When to Start, When to Stop, Which Drug to Choose, and How to Predict Response 2011 131 106 71%
Review article: the role of anti-TNF in the management of ulcerative colitis past, present and future 2013 33 20 95%

Address terms


Rank Address term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 INFLAMMATORY BOWEL DIS 18 14% 4.6% 116
2 U954 10 19% 1.8% 45
3 UNIV HOSP NANCY 9 32% 0.9% 24
4 INFLAMMATORY BOWEL DIS CLIN 9 19% 1.7% 43
5 IBD 6 16% 1.4% 36
6 MGH CROHNS COLITIS 6 38% 0.5% 13
7 ROBARTS CLIN TRIALS 6 30% 0.6% 16
8 AFDELING GASTROENTEROL 6 100% 0.2% 4
9 GLOBAL MED AFFAIRS GASTROENTEROL 6 100% 0.2% 4
10 HEALTHCARE EVALUAT UNIT 5 34% 0.5% 13

Related classes at same level (level 1)


Rank Relatedness score Related classes
1 0.0000271260 SEVERE ULCERATIVE COLITIS//TOXIC MEGACOLON//STEROID REFRACTORY ULCERATIVE COLITIS
2 0.0000160200 EPIDEMIOLOGY OF INFLAMMATORY BOWEL DISEASE//MONTREAL CLASSIFICATION//INDETERMINATE COLITIS
3 0.0000160104 FECAL CALPROTECTIN//CALPROTECTIN//FECAL ALPHA 1 ANTITRYPSIN
4 0.0000155997 DRUG INDUCED LUPUS//DRUG INDUCED LUPUS ERYTHEMATOSUS//TNF ALPHA ANTAGONISTS
5 0.0000155581 MESALAZINE//5 AMINOSALICYLIC ACID//MESALAMINE
6 0.0000151243 STRICTUREPLASTY//SURGICAL RECURRENCE//POSTOPERATIVE RECURRENCE
7 0.0000127886 INFLAMMATORY BOWEL DISEASE QUESTIONNAIRE//UBERT MARTIN INFLAMMATORY BOWEL DIS//UNITAT ATENCIO CROHN COLITIS
8 0.0000103516 THIOPURINE METHYLTRANSFERASE//6 MERCAPTOPURINE//THIOPURINE S METHYLTRANSFERASE
9 0.0000093981 DEXTRAN SULFATE SODIUM//EXPERIMENTAL COLITIS//BIOL CHEM BIOACT
10 0.0000088274 LEUKOCYTAPHERESIS//ADACOLUMN//GRANULOCYTE AND MONOCYTE ADSORPTION APHERESIS